Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2

I. Abbate, M. Guida, M. D. Musci, A. Casamassima, A. Latorre, L. Addabbo, C. D. Dragone, M. Cattedra, M. Correale, M. De Lena

Research output: Contribution to journalArticle

Abstract

Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.

Original languageEnglish
Pages (from-to)603-606
Number of pages4
JournalInternational Journal of Oncology
Volume3
Issue number4
Publication statusPublished - 1993

Fingerprint

Phagocytosis
Interleukin-2
Granulocytes
Monocytes
Macrophages
Complement C4
Neopterin
Interleukin-2 Receptors
Immunosuppressive Agents
Immunotherapy
Neutrophils
Cytokines
Incidence
Infection
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2. / Abbate, I.; Guida, M.; Musci, M. D.; Casamassima, A.; Latorre, A.; Addabbo, L.; Dragone, C. D.; Cattedra, M.; Correale, M.; De Lena, M.

In: International Journal of Oncology, Vol. 3, No. 4, 1993, p. 603-606.

Research output: Contribution to journalArticle

Abbate, I. ; Guida, M. ; Musci, M. D. ; Casamassima, A. ; Latorre, A. ; Addabbo, L. ; Dragone, C. D. ; Cattedra, M. ; Correale, M. ; De Lena, M. / Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2. In: International Journal of Oncology. 1993 ; Vol. 3, No. 4. pp. 603-606.
@article{5cc40b3911bb4f1091580f3c3b8b0a9f,
title = "Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2",
abstract = "Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.",
author = "I. Abbate and M. Guida and Musci, {M. D.} and A. Casamassima and A. Latorre and L. Addabbo and Dragone, {C. D.} and M. Cattedra and M. Correale and {De Lena}, M.",
year = "1993",
language = "English",
volume = "3",
pages = "603--606",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Evaluation of phagocytic activity in neoplastic patients treated with subcutaneous recombinant IL-2

AU - Abbate, I.

AU - Guida, M.

AU - Musci, M. D.

AU - Casamassima, A.

AU - Latorre, A.

AU - Addabbo, L.

AU - Dragone, C. D.

AU - Cattedra, M.

AU - Correale, M.

AU - De Lena, M.

PY - 1993

Y1 - 1993

N2 - Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.

AB - Immunostimulating and immunosuppressive events have been noted during rIL- 2 immunotherapy and cell-mediated immune deficiencies have been reported in the neutrophil and monocyte functions, determining a high incidence of infections in patients during intravenous rIL-2 treatment. The phagocytic activity of monocytes/macrophages and granulocytes was evaluated in 10 advanced solid tumor patients treated with subcutaneous rIL-2. Several indirect parameters of phagocytosis were also considered, such as Neopterin, Beta2 microglobulin, IL-2 soluble receptor, and the C3 and C4 fractions of the complement system. A decreased phagocytosis was demonstrated after subcutaneous rIL-2 administration together with an increase of indirect parameters of granulocyte/macrophage activity. Therefore, cellular activation does not seem to correspond to actual phagocytosis which is probably due to IL-2-induced secondary cytokines or to rIL-2 inhibitory effects.

UR - http://www.scopus.com/inward/record.url?scp=0027377979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027377979&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027377979

VL - 3

SP - 603

EP - 606

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -